Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27485803 | 0.92 | SMN1; SMN2 (0.42) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL16160087 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL275280 | 0.87 | SMN1; SMN2 (0.52) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL26658220 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL10805452 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL5076701 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL4476955 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL7096981 | 0.84 | SMN1; SMN2 (0.41) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| SCHEMBL31175938 | 0.82 | SMN1; SMN2 (0.35) | SMN1; SMN2CA14CA12ALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL8809999 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2CA14CA12ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-117980290-A | Cyanopyridine and cyanopyrimidine BCL6 degrading agents | 达纳－法伯癌症研究所公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170001983-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. | 2017-01-05 | — | — | US | disclosed |
| US-20170001983-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-1716135-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | Pfizer Limited (GB) | 2006-11-02 | — | — | EP | disclosed |
| US-7115757-B2 | Capable of inducing chemiluminescence; substrates for immunoassay; stability; low background for measurement to present high sensitivity | TOSOH CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| WO-2005077935-A1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LIMITED (GB) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-20050153365-A1 | 1, 2-dioxetane derivatives and reagents employing them | TOSOH CORPORATION (JP) | 2005-07-14 | — | — | US | disclosed |
| US-6844453-B2 | 1,2-Dioxetane derivatives and reagents employing them | TOSOH CORPORATION (JP) | 2005-01-18 | — | — | US | disclosed |
| US-20040176611-A1 | 1, 2-Dioxetane derivatives and reagents employing them | TOSOH CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| US-6747160-B2 | CAPABLE OF INDUCING CHEMILUMINESCENCE; SUBSTRATES FOR IMMUNOASSAY; STABLE; LOW BACKGROUND FOR MEASUREMENT TO PRESENT HIGH SENSITIVITY | TOSOH CORPORATION (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20030207329-A1 | 1, 2-Dioxetane derivatives and reagents employing them | TOSOH CORPORATION (JP) | 2003-11-06 | — | — | US | disclosed |
| EP-1342724-A1 | 1,2-dioxetane derivates and reagents employing them | Tosoh Corporation (JP) | 2003-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | SMN1; SMN2 859/4885CA14 4645/4885CA12 4514/4885 |
| US-20170001983-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | SMN1; SMN2 859/4885CA14 4645/4885CA12 4514/4885 |
| US-20050153365-A1 | 1, 2-dioxetane derivatives and reagents employing them | DAO, AKR1B10, OXSR1 | SMN1; SMN2 4357/4885CA14 2271/4885CA12 3041/4885 |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | BCL6, BCL6B, BCOR | SMN1; SMN2 2805/4885CA14 3288/4885CA12 3050/4885 |
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | SMN1; SMN2 2155/4885CA14 3173/4885CA12 4038/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | SMN1; SMN2 859/4885CA14 4645/4885CA12 4514/4885 |
| US-20030207329-A1 | 1, 2-Dioxetane derivatives and reagents employing them | SRD5A1, DAO, SRD5A2 | SMN1; SMN2 4205/4885CA14 1880/4885CA12 3349/4885 |
| US-20040176611-A1 | 1, 2-Dioxetane derivatives and reagents employing them | SRD5A1, DAO, SRD5A2 | SMN1; SMN2 4205/4885CA14 1880/4885CA12 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.